Drug Profile

MRX 4

Alternative Names: MRX-4

Latest Information Update: 28 May 2015

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Morria Biopharmaceuticals
Developer Celsus Therapeutics
Class Anti-inflammatories
Mechanism of Action Phospholipase A2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Allergic rhinitis

Most Recent Events

06 Mar 2013 Morria Biopharmaceuticals is now called Celsus Therapeutics
31 Dec 2012 Celsus Therapeutics plans a phase IIb trial for Allergic rhinitis in Austria
17 Jun 2010 Final safety and efficacy data from a phase II trial in Allergic rhinitis released by Morria Biopharmaceuticals

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com